The use of growth hormone (GH) therapy in short stature
| NICE, National Institute for Clinical Excellence. |
| • Treatment recommended by NICE guidelines 2002 in the UK1 |
| ‐ GH deficiency, isolated or as part of multiple pituitary hormone deficiency |
| ‐ Turner syndrome |
| ‐ Prader Willi syndrome |
| ‐ Short stature associated with chronic renal failure |
| • Licensed indications in Europe |
| ‐ GH deficiency, isolated or as part of multiple pituitary hormone deficiency |
| ‐ Turner syndrome |
| ‐ Prader Willi syndrome |
| ‐ Short stature associated with chronic renal failure |
| ‐ Short stature associated with low birth weight |
| • Licensed in the USA, but not in Europe |
| ‐ Idiopathic short stature |
| • Short stature conditions where there have been trials of treatment with GH but outcome is not clear (not licensed indications) |
| ‐ Noonan syndrome |
| ‐ Skeletal dysplasia |
| ‐ Rheumatoid arthritis |
| ‐ Down syndrome |
| ‐ Short stature associated with prolonged steroid use |
| ‐ Aarskog’s syndrome |